Asan Medical Center Researchers Announce 'Obesity Rate of Inflammatory Bowel Disease Patients Increased 2.3 Times Over 13 Years'

The obesity rate of patients with inflammatory bowel disease, previously known as a 'weight-loss disease', has recently increased 2.3 times over the past 13 years. According to research results announced by the team of Professors Hwang Seong-wook and Kim Min-kyu at the Inflammatory Bowel Disease Center of Asan Medical Center on the 28th, an analysis of 11,216 inflammatory bowel disease patients from 2008 to 2021 revealed that the average obesity rate surged from 13.1% to 29.8%.

Inflammatory Bowel Disease Gaining Attention Due to Celebrity Confessions

Inflammatory bowel disease includes Crohn's disease and ulcerative colitis, with singer Yoon Jong-shin being a well-known patient. Last month, Yoon Jong-shin expressed his daily struggles on social media, stating, 'I had a Crohn's pain after a long time. I couldn't eat with my golfing companions and just left.' He revealed his battle with Crohn's disease on a variety show in 2012, saying, 'In the end, my small intestine narrowed too much, and I had to undergo surgery to remove 60 cm,' which garnered sympathy from many.

Abroad, MrBeast, the world's number one YouTuber with 416 million subscribers, is also a Crohn's disease patient. He confessed that he experienced a rapid weight loss from 86 kg to 63 kg due to this condition during his teenage years. Traditionally, inflammatory bowel disease has been characterized by weight loss due to gastrointestinal symptoms.

Largest Domestic Study Tracking Over 13 Years

This study conducted by researchers at Asan Medical Center is considered the largest long-term follow-up study of inflammatory bowel disease patients conducted in Asia. The research team systematically analyzed the changes in body mass index (BMI) of 11,216 inflammatory bowel disease patients who visited the hospital from 2008 to 2021.

The study found that the average obesity rate of patients surged from 13.1% in 2008 to 29.8% in 2021. This is about 3.6 times higher than the increase in obesity rates in the general population during the same period (30.7%→37.1%, an increase of 6.4%). Notably, the rate of increase in obesity among inflammatory bowel disease patients significantly exceeds that of the general population.

Significant Surge in Obesity Rates Among Male Patients

Gender analysis revealed even more surprising differences. The obesity rate among male patients rose dramatically from 15.1% in 2008 to 37.7% in 2021, an increase of 22.6%, while female patients only increased from 9.2% to 15.0%, a rise of 5.8%. The increase in obesity rates among male patients was found to be about four times higher than that of females.

This gender difference is analyzed to be influenced by various factors, including hormonal factors, differences in lifestyle, and coping mechanisms for the disease. It has been suggested that male patients may be relatively neglectful of lifestyle improvements such as diet management and exercise.

Accompanying Deterioration of Metabolic Syndrome Indicators

Along with the increase in obesity rates, hematological indicators related to metabolic syndrome also showed signs of deterioration. According to the researchers' analysis, patients' blood sugar levels tended to rise above the normal range (70-99 mg/dL), and total cholesterol levels continuously increased within the normal range.

In particular, the triglyceride levels of Crohn's disease patients rose from an appropriate level in 2008 to a borderline level of over 150 mg/dL in 2021. This is an important indicator suggesting that patients' overall metabolic health is deteriorating beyond simple weight gain.

Impact of Westernized Lifestyle

The researchers identified Westernized eating habits and lifestyles as the main causes of these changes. Compared to the past, the intake of high-calorie and high-fat foods has increased, while physical activity has decreased, exposing inflammatory bowel disease patients to obesity risks similar to those of the general population.

Additionally, advancements in treatment technologies have improved patients' symptoms, leading to a recovery of appetite and nutritional status, which may have contributed to weight gain. In the past, sufficient nutritional intake was difficult due to continuous inflammation and digestive disorders, but the introduction of modern treatment methods has alleviated these constraints.

Need for Comprehensive Treatment Strategies

Managing obesity in inflammatory bowel disease patients requires a much more complex approach than in the general population. Patients face various constraints such as a history of bowel resection surgery, side effects of medications, and dietary restrictions, making it difficult to apply standard obesity treatment methods.

In particular, the long-term use of steroid medications can lead to weight gain and metabolic disorders, and patients who have undergone bowel resection require a more cautious approach to weight management due to issues with nutrient absorption. Furthermore, the range of dietary adjustments may vary depending on the activity level of the disease, necessitating individualized management strategies.

Impact on Long-Term Prognosis

Obesity and metabolic syndrome are known to be significant risk factors that worsen the prognosis of inflammatory bowel disease. Obese inflammatory bowel disease patients have a higher recurrence rate of the disease, poorer response to treatment, and an increased risk of various complications, including cardiovascular diseases.

Moreover, obesity can sustain a chronic inflammatory state, further exacerbating intestinal inflammation and acting as a factor that reduces the effectiveness of immunomodulatory therapies. This leads to prolonged treatment periods and increased medical costs, placing a burden on both patients and healthcare providers.

Foundation for Developing Asian-Specific Treatment Standards

This study is significant as it breaks away from Western-centric obesity standards and represents the largest analysis of inflammatory bowel disease patient data focused on Asians to date. Previous related research has primarily been conducted in the West, and there has been a lack of research data reflecting the physiological characteristics and living environments of Asians.

Professor Hwang Seong-wook stated, 'In a situation where there is a lack of clinical evidence regarding obesity in Asian inflammatory bowel disease patients, we have obtained important research results proving the correlation between inflammatory bowel disease and obesity rates,' and added, 'Based on this research, we will focus on developing treatment strategies that consider individual patient characteristics and can aid in long-term prognosis.'

Internationally Recognized Research Achievements

The results of this study were published in the latest issue of the prestigious international journal in the field of gastroenterology, the 'Journal of Gastroenterology'. This indicates that the methodology and results of the research have been recognized at an international level and are expected to serve as important reference materials for the development of global inflammatory bowel disease treatment guidelines in the future.

The research team announced plans to develop practical treatment protocols for the prevention and management of obesity in inflammatory bowel disease patients based on the results of this study. They also plan to expand the clinical application of research results through the creation of patient education programs and lifestyle improvement guidelines.